Tumor volume determines the feasibility of cell-free DNA sequencing for mutation detection in non-small cell lung cancer

Tatsuo Ohira, Kazuko Sakai, Jun Matsubayashi, Naohiro Kajiwara, Masatoshi Kakihana, Masaru Hagiwara, Masaaki Hibi, Koichi Yoshida, Junichi Maeda, Keishi Ohtani, Toshitaka Nagao, Kazuto Nishio and Norihiko Ikeda

1Department of Surgery, Tokyo Medical University, Tokyo; 2Department of Genome Biology, Kindai University Faculty of Medicine, Osaka-Sayama; 3Department of Anatomic Pathology, Tokyo Medical University, Tokyo, Japan

Key words
Cell-free DNA, mutation, non-small cell lung cancer, sequencing, tumor volume

Correspondence
Kazuto Nishio, Department of Genome Biology, Kindai University Faculty of Medicine, 377-2 Onno-higashi, Osaka-Sayama, Osaka 589-8511, Japan. Tel: +81-72-366-0221; Fax: +81-72-367-6369; E-mail: knishio@med.kindai.ac.jp

Funding Information
Applied Research for Innovative Treatment of Cancer (14525177) Ministry of Health, Labor, and Welfare of Japan.

*These authors contributed equally to this study.

Received April 7, 2016; Revised August 24, 2016; Accepted August 27, 2016

Cancer Sci 107 (2016) 1660–1666
doi: 10.1111/cas.13068

Next-generation sequencing (NGS) and digital PCR technologies allow analysis of the mutational profile of circulating cell-free DNA (cfDNA) in individuals with advanced lung cancer. We have now evaluated the feasibility of cfDNA sequencing for mutation detection in patients with non-small cell lung cancer at earlier stages. A total of 150 matched tumor and serum samples were collected from non-small cell lung cancer patients at stages IA–IIIA. Amplicon sequencing with DNA extracted from tumor tissue detected frequent mutations in EGFR (37% of patients), TP53 (39%), and KRAS (10%), consistent with previous findings. In contrast, NGS of cfDNA identified only EGFR, TP53, and PIK3CA mutations in three, five, and one patient, respectively, even though adequate amounts of cfDNA were extracted (median of 4936 copies/mL serum). Next-generation sequencing showed a high accuracy (98.8%) compared with droplet digital PCR for cfDNA mutation detection, suggesting that the low frequency of mutations in cfDNA was not due to a low assay sensitivity. Whereas the yield of cfDNA did not differ among tumor stages, the cfDNA mutations were detected in seven patients at stages IIa–IIIA and at T2b or T3. Tumor volume was significantly higher in the cfDNA mutation-positive patients than in the negative patients at stages T2b–T4 (159.1 ± 58.0 vs. 52.5 ± 9.9 cm³, P = 0.014). Our results thus suggest that tumor volume is a determinant of the feasibility of mutation detection with cfDNA as the analyte.

Lung cancer is the leading cause of death related to cancer worldwide, with non-small cell lung cancer (NSCLC) being the most common form of this disease. Targeted therapeutics such as tyrosine kinase inhibitors of the epidermal growth factor receptor (EGFR) or anaplastic lymphoma kinase (ALK) have recently been introduced into clinical practice for individuals with NSCLC positive for actionable mutations of EGFR or ALK fusions, respectively. Molecular profiling that is able to predict the response to such drugs has thus become an important therapeutic strategy, allowing selection of the most appropriate treatment for individual patients. This strategy is limited, however, by the difficulty of obtaining tumor specimens, the collection of which often requires invasive procedures.

Sequencing of circulating cell-free DNA (cfDNA), a non-invasive approach to the detection of aberrant tumor-derived DNA in blood, has the potential to allow early identification and management of solid tumors as well as prediction of drug sensitivity or resistance. Several studies have evaluated cfDNA as a potential biomarker in NSCLC patients, who tend to have a higher plasma cfDNA concentration than healthy individuals.

Tumors at an advanced stage often shed cfDNA into the circulation, and mutations in this cfDNA can be detected with PCR-based or sequencing-based assays. Deep sequencing of amplicons has proved feasible for the detection of somatic mutations in cfDNA if the total number of reads exceeds 300 000. Digital PCR is also a highly sensitive technology that allows the detection of mutations in cfDNA with a high accuracy relative to those in tumor cell DNA in individuals with advanced lung cancer. The clinicopathologic factors that are associated with the feasibility of mutation identification in cfDNA remain unknown, however. We have now compared the mutation profiles of surgically resected tumor specimens from patients with NSCLC of stage IA to IIIA with those of matched serum samples in order to ascertain the feasibility of mutation detection in cfDNA at such early disease stages as well as its determinant factors.

Materials and Methods

Patients and specimen collection. Matched lung cancer tissue and serum specimens were collected from 150 patients who underwent surgery for NSCLC at Tokyo Medical University Hospital (Tokyo, Japan) from January 2013 to July 2014. All tissue samples were immediately flash-frozen in liquid nitrogen and stored at -80°C until analysis. Tumor volume was...
calculated as length × width × height during surgery. Blood samples were also collected during surgery and were centrifuged at 1400 g for 10 min, with serum being stored at −80°C until analysis. All patients provided written informed consent to participate in the study, including the collection of tumor and serum specimens for analysis. The study protocol was approved by the institutional ethics committees of Kindai University Faculty of Medicine (Osaka-Sayama, Japan; approval no. 253135) and Tokyo Medical University Hospital (approval no. 2541).

DNA was isolated from the frozen tumor tissue with the use of an AllPrep DNA/RNA Mini Kit (Qiagen, Valencia, CA, USA). The quality and quantity of the DNA were verified with the use of a NanoDrop 2000 device (Thermo Fisher Scientific, Waltham, MA, USA) and PicoGreen dsDNA Assay Kit (Life Technologies, Foster City, CA, USA). Cell-free DNA was purified from 0.52 to 1.0 mL serum with the use of a QIAamp Circulating Nucleic Acid Kit (Qiagen), and its copy number was determined with an RNaseP copy number assay (Life Technologies).

**Sample processing.** **Sequencing analysis.** Tumor DNA and cfDNA samples were subjected to analysis with next-generation sequencing (NGS) panels for mutation detection. For library preparation, tumor DNA (10 ng) and cfDNA (maximum of 3000 copies) were subjected to multiplex PCR amplification with the use of an Ion AmpliSeq Library Kit 2.0 (Life Technologies) and Ion AmpliSeq Colon and Lung Cancer Panel version 2 (Life Technologies), the latter of which targets mutational hotspot regions of 22 cancer-associated genes: AKT1, ALK, BRAF, CTNNB1, DDR2, EGFR, ERBB2, ERBB4, FBXW7, FGFR1, FGFR2, FGFR3, KRAS, MAP2K1, MET, NOTCH1, NRAS, PIK3CA, PTEN, SMAD4, STK11, and TP53. The PCR products were then ligated into Ion Xpress Barcode Adapters (Life Technologies) and purified with the use of Agencourt AMPure XP beads (Beckman Coulter, Brea, CA, USA). The purified libraries were pooled and then sequenced with an Ion Torrent Proton instrument. Ion Proton Hi-Q Sequencing Kit, and Ion PI version 3 Chip (all from Life Technologies). DNA sequencing data were accessed through the Torrent Suite version 4.4 program (Life Technologies). Reads were aligned with the hg19 human reference genome, and variants were called with the use of Variant Call Format version 4.4. Samples with a median coverage of <1000 per amplicon were not accepted for evaluation. For detection of mutations in tumor tissue DNA, raw variant calls were filtered with the following annotations: quality score of <100 and depth of coverage of <19. Germline mutations were excluded with the use of the Human Genetic Variation Database (http://www.genome.med.kyoto-u.ac.jp/SnpDB). For cfDNA mutation detection, the nucleotide count for each target base position from each allele count file in the variant calling report was used. The presence of mutant nucleotides was determined with the use of Poisson distribution statistics. The nucleotide count for each base position was applied to the Poisson function with the use of Microsoft Excel 2013 (Redmond, WA, USA). The value of the baseline error rate (non-reference nucleotide count divided by the total nucleotide count) plus three standard deviations calculated from 10 normal blood DNA samples was used for the Poisson parameter lambda ($\lambda$) ranging from 0.00045 to 0.11859. If the nucleotide count of the mutant was significantly higher ($\alpha = 2 \times 10^{-5}$) than that of the Poisson probability, the nucleotide was judged to have a mutation-positive status. We established the $\alpha$ value with reference to a previous study. The minimum detection limit was calculated for a read number per site of 30,000 and $\alpha$ of 0.00002, with all values being shown in Table S1. The Ion AmpliSeq Colon and Lung Cancer Panel version 2 is designed to amplify 92 amplicons covering 1205 hot spot mutations. The theoretical minimum detection limit ranged from 12.7% to 0.103% and was <0.5% for 84.4% (1017/1205) of hot spot sites.

**Digital PCR analysis.** Digital PCR was carried out with a QX100 Droplet Digital PCR System (Bio-Rad, Hercules, CA, USA). The primers and probes for detection of the EGFR L858R, KRAS G12C, and PIK3CA E545K and H1047R mutations were obtained from Bio-Rad. The cycling conditions included an initial incubation at 95°C for 10 min, 40 cycles of 94°C for 30 s and 55°C for 60 s, and enzyme inactivation at 98°C for 10 min. After thermal cycling, the plates were transferred to a Droplet reader (Bio-Rad), and the digital PCR data were analyzed with the Quanta Soft analytic software package (Bio-Rad). The cutoff values for mutations were determined with the use of plasma cfDNA and normal blood DNA derived from 10 healthy volunteers. Each cut-off was set at 3 copies per one reaction because no background noise (0 copies per one reaction) was detected for any of the mutants in plasma cfDNA and normal blood DNA derived from the 10 healthy volunteers.

**Statistical analysis.** Statistical analysis was carried out using the two-tailed Student’s t-test (Prism software; GraphPad Software, San Diego, CA, USA). A $P$-value of < 0.05 was considered statistically significant.

### Results

**Somatic mutations detected in lung cancer tissue by NGS.** Frozen surgically resected tumor tissue and matched serum samples were obtained from 150 NSCLC patients (Table 1).

| Characteristic | Classification | No. (%) |
|----------------|----------------|---------|
| Age, years     | Median (range) | 69 (23–85) |
|                | <65            | 51 (34.0) |
|                | ≥65            | 99 (66.0) |
| Sex            | Male           | 80 (53.3) |
|                | Female         | 70 (46.7) |
| Smoking status | Yes            | 97 (64.7) |
|                | No             | 48 (32.0) |
|                | Unknown        | 5 (3.3) |
| Pathological stage | IA        | 63 (42.0) |
|                 | IB             | 32 (21.3) |
|                 | II A           | 20 (13.3) |
|                 | III B          | 10 (6.7) |
|                 | III A          | 25 (16.7) |
| Tumor size (T stage) | T1a      | 39 (26.0) |
|                 | T1b            | 36 (24.0) |
|                 | T2a            | 44 (29.3) |
|                 | T2b            | 10 (6.7) |
|                 | T3             | 20 (13.3) |
|                 | T4             | 1 (0.7) |
| Lymph node metastasis (N stage) | N0     | 104 (69.3) |
|                 | N1             | 19 (12.7) |
|                 | N2             | 21 (14.0) |
|                 | NX             | 6 (4.0) |
All tumor DNA samples were successfully sequenced with the Ion Proton platform. The median read number per amplicon was 15,632, with a range of 1272 to 323,280 (Fig. S1). We identified TP53 mutations in 58 cases (38.7%), EGFR mutations in 56 (37.3%), KRAS mutations in 15 (10.0%), CTNNB1 mutations in 7 (4.7%), ERBB2, PIK3CA, BRAF, and PTEN mutations in 3 each (2.0%), and ERBB4, MET, ALK, FGFR2, NRAS, AKT1, and FBXW7 mutations in 1 each (0.7%) (Fig. 1a). No mutation was detected in 22.0% (33/150) of the samples. Mutation profiles for patients harboring at least one mutation are shown in Figure 1(b).

Somatic mutations detected in cfDNA by NGS. Serum cfDNA was extracted for all 150 patients, with a median yield (copy number) of 4936 (range, 572–373,658) (Fig. S2). A total of 149 of the 150 (99.3%) cfDNA samples were successfully sequenced with the Ion Proton platform, with sequencing failure being due to an insufficient read number per amplicon (case no. 200, 197 reads) in the one unsuccessful case. The median read number per amplicon for the 149 successfully sequenced cfDNA samples was 33,982, with a range of 1563–63,601 (Fig. S1).

We identified only a small number of non-synonymous somatic mutations in cfDNA, including TP53 mutations in 5 cases (3.3%), EGFR mutations in 3 cases (2.0%), and a PIK3CA mutation in 1 case (0.7%) (Fig. 1a). The mutation profiles for patients harboring cfDNA mutations are shown in Figure 1(b). Compared with tumor tissue samples, the sensitivity and specificity for mutation detection in serum were 5.8% (9/155) and 100% (33/33), respectively, with an accuracy of 22.3% (42/188).

Accuracy of somatic mutation detection by NGS and digital PCR. To exclude the possibility of false negative results generated by NGS, we applied digital PCR to confirm mutations detected with NGS. The L858R mutation of EGFR, G12C of KRAS, and E545K and H1047R of PIK3CA accounted for a substantial proportion of the mutations detected in the tumor samples with NGS. The 42 tumor samples determined to be positive for these mutations by NGS and the paired serum samples were therefore analyzed for the same mutations with digital PCR (Table 2). For the 42 tumor samples, all of the mutations detected by NGS were also detected by digital PCR. For the corresponding serum samples, the two mutations (EGFR L858R in case no. 79 and PIK3CA E545K in case no. 65) detected by NGS were confirmed with digital PCR; only one mutation (KRAS G12C in case no. 215) was detected in the remaining 40 serum samples by digital PCR. Compared with digital PCR, the sensitivity and specificity of NGS for mutation detection were 97.8% (44/45) and 100% (39/39), respectively, with an accuracy of 98.8% (83/84).

A comparison of variant allele frequency revealed a high correlation ($R^2 = 0.992$) between NGS and digital PCR for 30 tumor specimens positive for EGFR L858R (Fig. 2). We further examined the ability of NGS to detect mutant alleles by comparing the fraction of variant reads for these 30 tumor specimens positive for EGFR L858R with the corresponding allele copy number determined by digital PCR. The two parameters showed a good linear correlation ($R^2 = 0.893$) (Fig. S3), suggesting that the power of NGS for mutation detection was equivalent to that of digital PCR.

To clear the baseline error rate in NGS assay, we measured the rate of two sample cohorts: 36 cfDNA samples in lung...
cancer patients with KRAS or EGFR exon 19 deletion mutation (KRAS/EGFRex19del) in tumor and 32 cfDNA samples in patients without any mutation in the tumor. Median allele frequency of cfDNA samples at position EGFR L858R (chr7:55259515) of NGS assay was 0.00631 (range, 0–0.04392) in tumor KRAS/EGFRex19del-positive and no mutation groups, respectively. In addition, we examined the EGFR L858R mutation in cfDNA samples by digital PCR assay in these two groups.

| Mutation  | Case no. | NGS (% of variant reads) | Digital PCR (copy number) |
|-----------|----------|--------------------------|--------------------------|
|           |          | Tumor | Serum | Tumor | Serum |
| EGFR L858R | 55       | 16.3 | n.d.  | 2520 | n.d.  |
|           | 66       | 45.8 | n.d.  | 4880 | n.d.  |
|           | 71       | 24.2 | n.d.  | 2280 | n.d.  |
|           | 74       | 33.4 | n.d.  | 2240 | n.d.  |
|           | 79       | 100.0| 0.6   | 16660| 74    |
|           | 82       | 18.5 | n.d.  | 1208 | n.d.  |
|           | 86       | 35.7 | n.d.  | 4160 | n.d.  |
|           | 103      | 43.6 | n.d.  | 3720 | n.d.  |
|           | 105      | 15.1 | n.d.  | 1150 | n.d.  |
|           | 114      | 26.8 | n.d.  | 1740 | n.d.  |
|           | 117      | 23.6 | n.d.  | 3040 | n.d.  |
|           | 118      | 15.6 | n.d.  | 1064 | n.d.  |
|           | 126      | 41.8 | n.d.  | 4000 | n.d.  |
|           | 135      | 26.2 | n.d.  | 1900 | n.d.  |
|           | 142      | 10.4 | n.d.  | 680  | n.d.  |
|           | 143      | 7.8  | n.d.  | 566  | n.d.  |
|           | 155      | 25.6 | n.d.  | 2340 | n.d.  |
|           | 156      | 28.7 | n.d.  | 2340 | n.d.  |
|           | 161      | 19.9 | n.d.  | 2000 | n.d.  |
|           | 164      | 18.0 | n.d.  | 1286 | n.d.  |
|           | 168      | 33.5 | n.d.  | 6240 | n.d.  |
|           | 171      | 27.9 | n.d.  | 2280 | n.d.  |
|           | 176      | 32.2 | n.d.  | 3320 | n.d.  |
|           | 177      | 57.1 | n.d.  | 8720 | n.d.  |
|           | 192      | 4.3  | n.d.  | 186  | n.d.  |
|           | 204      | 49.0 | n.d.  | 5460 | n.d.  |
|           | 208      | 35.7 | n.d.  | 3240 | n.d.  |
|           | 209      | 25.7 | n.d.  | 1580 | n.d.  |
|           | 212      | 11.8 | n.d.  | 1100 | n.d.  |
|           | 220      | 4.5  | n.d.  | 238  | n.d.  |
| KRAS G12C  | 73       | 4.9  | n.d.  | 278  | n.d.  |
|           | 78       | 24.2 | n.d.  | 2200 | n.d.  |
|           | 120      | 6.6  | n.d.  | 858  | n.d.  |
|           | 123      | 15.8 | n.d.  | 1528 | n.d.  |
|           | 149      | 4.2  | n.d.  | 352  | n.d.  |
|           | 162      | 12.8 | n.d.  | 1228 | n.d.  |
|           | 194      | 30.9 | n.d.  | 2540 | n.d.  |
|           | 206      | 12.0 | n.d.  | 882  | n.d.  |
|           | 215      | 32.4 | n.d.  | 2560 | 4    |
| PIK3CA E545K | 65 | 58.6 | 3.5 | 11260 | 43 |
|           | 184      | 31.2 | n.d.  | 2660 | n.d.  |
| PIK3CA H1047R | 138 | 24.9 | n.d.  | 1499 | n.d.  |

n.d., not detected.
tumor diameter calculated at diagnosis was also larger in the cfDNA mutation-positive group than in the cfDNA mutation-negative group (5.3 ± 0.7 vs. 4.1 ± 0.3 cm, \( P = 0.050 \)) (Fig. 4e). These results suggested that tumor volume is a determining factor for the feasibility of mutation detection with cfDNA.

**Discussion**

Mutation profiling by NGS with tumor biopsy specimens has recently become established, with \( EGF R \), \( TP 53 \), and \( K R A S \) genes having been found to be frequently mutated in lung cancer specimens from Japanese patients.\(^{(2)}\) In the present study,
mutations of \( \text{EGFR} \), \( \text{TP53} \), and \( \text{KRAS} \) were also frequently detected in NSCLC specimens, with those in \( \text{KRAS} \) and \( \text{EGFR} \) being mutually exclusive. Mutations in the genes analyzed were detected in 78.0% of tumor samples, with the mutation profiles being consistent with those observed previously. The purpose of the present study was to investigate the mutation status for cfDNA isolated from serum of patients with NSCLC at an early stage. In comparison with matched tumor tissue, the sensitivity for mutation detection in serum by NGS was low (5.8%), consistent with previous results. It thus appears to be difficult to detect mutations in cfDNA for patients with NSCLC at an early stage. In contrast, previous studies have reported a sensitivity of 70–80% for detection of \( \text{EGFR} \) mutations in plasma DNA compared with matched tumor DNA of patients with advanced NSCLC by beaming or digital PCR. We previously found the sensitivity for detection of activating mutations of \( \text{EGFR} \) in plasma cfDNA of such patients by digital PCR to be 66.7%. The feasibility of cfDNA sequencing is thought to be limited by the copy number of the DNA extracted from serum or plasma samples. The median copy number for the total of 150 samples in the present study was 4936, and library preparation and NGS were successful for 149 of these samples (99.3%). It is therefore unlikely that an insufficient amount of cfDNA was responsible for the low mutation frequency of cfDNA in our cohort. However, amplicons for NGS are derived from wild-type as well as variant alleles, with a low frequency of mutant alleles compared with the wild-type allele making it difficult to detect the former. The amplicon sequencing system was thus a possible limiting factor in our NGS assay. We therefore applied digital PCR to exclude this technical issue. The mutational status of cfDNA determined by NGS was confirmed with digital PCR, with the two approaches showing a high concordance. We therefore conclude that the NGS assay had sufficient power to detect a low frequency of mutations in serum, and that the discordance between the results obtained with tumor DNA and serum cfDNA was not due to the sensitivity of the NGS technology. The proportion of serum cfDNA that is derived from tumor cells thus appears to be much lower for patients with NSCLC at the resectable stage than for those with such tumors at an advanced stage. Our findings are consistent with those reported for different types of cancer including primary brain, renal, prostate, and thyroid tumors. We examined whether clinicopathologic features of the study patients might have influenced the mutation detection rate with cfDNA. The seven cfDNA mutation-positive cases detected by NGS were all stage T2b or higher, suggesting that tumor volume is related to the rate of mutation detection in serum. The relation between the \( T \) factor and mutation detection in cfDNA, including the clinical relevance of mutation detection in cfDNA derived from patients with an advanced \( T \) factor, even at an early pathological stage, requires further validation. Lymph node metastasis (N stage) did not appear to be a possible limiting factor, even at an early pathological stage, requires further validation. Lymph node metastasis (N stage) did not appear to be the lymphatic system might not play a major role in the spread of tumor cells into the circulation.

In conclusion, we found that 78.0% of resected NSCLC tumors harbored at least one mutation as detected by NGS. The incidence of cfDNA mutations in patients with early stage NSCLC was extremely low, however. Next-generation sequencing showed a high accuracy compared with digital PCR for detection of mutations, indicating that NGS technology is similarly useful for the monitoring of mutant alleles. Given the multiplex nature of NGS, it is likely to become more widely adopted for monitoring of tumor progression and recurrence with cfDNA as the analyte.
Acknowledgments

We thank K. Nagase, Y. Hosono, T. Miyazaki, and A. Kurumatani for cooperation and assistance. This work was supported by Applied Research for Innovative Treatment of Cancer (subject no. 14525177 to K.N.) from the Ministry of Health, Labor, and Welfare of Japan.

References

1 Siegel R, Ma J, Zou Z, Jemal A. Cancer statistics, 2014. CA Cancer J Clin 2014; 64: 9–29.
2 Takeda M, Sakai K, Terashima M et al. Clinical application of amplicon-based next-generation sequencing to therapeutic decision making in lung cancer. Ann Oncol 2015; 26: 2477–82.
3 van der Drift MA, Hol BE, Klaassen CH et al. Circulating DNA is a non-invasive prognostic factor for survival in non-small cell lung cancer. Lung Cancer 2010; 68: 283–7.
4 Lee YJ, Yoon KA, Han JY et al. Circulating cell-free DNA in plasma of never smokers with advanced lung adenocarcinoma receiving gefitinib or standard chemotherapy as first-line therapy. Clin Cancer Res 2011; 17: 5179–87.
5 Couraud S, Vaca-Paniagua F, Villar S et al. Noninvasive diagnosis of actionable mutations by deep sequencing of circulating free DNA in lung cancer from never-smokers: a proof-of-concept study from BioCAST/IFCT-1002. Clin Cancer Res 2014; 20: 4613–24.
6 Kimura H, Fujiwara Y, Sone T et al. EGFR mutation status in tumour-derived DNA from pleural effusion fluid is a practical basis for predicting the response to gefitinib. Br J Cancer 2006; 95: 1390–5.
7 Tamiguchi K, Uchida J, Nishino K et al. Quantitative detection of EGFR mutations in circulating tumor DNA derived from lung adenocarcinomas. Clin Cancer Res 2011; 17: 7808–15.
8 Douillard JY, Ostoros G, Cobo M et al. First-line gefitinib in Caucasian EGFR mutation-positive NSCLC patients: a phase-IV, open-label, single-arm study. Br J Cancer 2014; 110: 55–62.
9 Oxnard GR, Paweletz CP, Kuang Y et al. Noninvasive detection of response and resistance in EGFR-mutant lung cancer using quantitative next-generation genotyping of cell-free plasma DNA. Clin Cancer Res 2014; 20: 1698–705.
10 Ishii H, Azuma K, Sakai K et al. Digital PCR analysis of plasma cell-free DNA for non-invasive detection of drug resistance mechanisms in EGFR mutant NSCLC: correlation with paired tumor samples. Oncotarget 2015; 6: 30850–8.
11 Kukita Y, Uchida J, Oba S et al. Quantitative identification of mutant alleles derived from lung cancer in plasma cell-free DNA via anomaly detection using deep sequencing data. PLoS ONE 2013; 8: e81468.
12 Paweletz CP, Sacher A, Raymond CK et al. Bias-corrected targeted next-generation sequencing for rapid, multiplexed detection of actionable alterations in cell-free DNA from advanced lung cancer patients. Clin Cancer Res 2015; 22: 915–22.
13 Sakai K, Tsurutani J, Yamanaka T et al. Extended RAS and BRAF mutation analysis using next-generation sequencing. PLoS ONE 2015; 10: e0121891.
14 Narahara M, Higasa K, Nakamura S et al. Large-scale East-Asian eQTL mapping reveals novel candidate genes for LD mapping and the genomic landscape of transcriptional effects of sequence variants. PLoS ONE 2014; 9: e100924.
15 Okamoto I, Sakai K, Morita S et al. Multiplex genomic profiling of non-small cell lung cancers from the LETS phase III trial of first-line S-1/carboplatin versus paclitaxel/carboplatin: results of a West Japan Oncology Group study. Oncotarget 2014; 5: 2293–304.
16 Sholl LM, Ainoz DL, Varella-Garcia M et al. Multi-institutional oncogenic driver mutation analysis in lung adenocarcinoma: the Lung Cancer Mutation Consortium experience. J Thorac Oncol 2015; 10: 768–77.
17 Zhao X, Han RB, Zhao J et al. Comparison of epidermal growth factor receptor mutation statuses in tissue and plasma in stage I-IV non-small cell lung cancer patients. Respiration 2013; 85: 119–25.
18 Guo K, Zhang Z, Han L et al. Detection of epidermal growth factor receptor mutation in plasma as a biomarker in Chinese patients with early-stage non-small cell lung cancer. Oncotarget 2015; 8: 3289–96.
19 Betegowda C, Sleeuw M, Leary RJ et al. Detection of circulating tumor DNA in early- and late-stage human malignancies. Sci Transl Med 2014; 6: 224ra24.

Supporting Information

Additional Supporting Information may be found online in the supporting information tab for this article:

Fig. S1. Median next-generation sequencing read number per amplicon for all 150 non-small cell lung carcinoma tumor and serum samples.

Fig. S2. Yield of cell-free DNA (cfDNA) for all 150 serum samples from patients with non-small cell lung carcinoma.

Fig. S3. Correlation between next-generation sequencing (NGS) and digital PCR data.

Fig. S4. Allele frequency at EGFR L858R position using next-generation sequencing and digital PCR assay.

Table S1. Poisson parameter (λ) and theoretical minimum detection limit (MDL) for next-generation sequencing with the Ion AmpliSeq Colon and Lung Cancer Panel version 2 (Life Technologies, Foster City, CA, USA).